# US 2014/0234212 A1 · Targeted Buccal Delivery of Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0234212 A1
- Document ID: US20140234212A1
- Status: Published application
- Kind: A1
- Application number: 14/186,977
- Filed: 2014-02-21
- Published: 2014-08-21
- Earliest claimed: 2013-02-21
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Manijeh Nazari Goldberg; Maria Jose Alonso; Kuan-Ju Chen
- Web page: https://patentgrep.com/patent/US20140234212A1

## CPC

- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A23L 29/275: of animal origin, e.g. chitin
- A23L 29/35: {Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches}
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23P 10/00: Shaping or working of foodstuffs characterised by the products
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/242: Gold; Compounds thereof
- A61K 33/243: Platinum; Compounds thereof
- A61K 49/0017: {Fluorescence in vivo}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23P: SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

A delivery device for topical and systemic delivery of agents to targeted oral locations, such as mouth cancer cells, has been developed. The formulation includes a mucoadhesive polymeric matrix such as chitosan, which contains one or more therapeutic and/or diagnostic agents, taste masking agents, permeation enhancers, the therapeutic or diagnostic agent to be delivered, and a hydrophilic polymeric coating such as polyethyleneglycol (“PEG”). In the preferred embodiment, the matrix is formulated with one side having the PEG-mucoadhesive polymer exposed for topical placement onto epithelial or cancer cells in the mouth or other mucosal area and the side(s) facing the inside of the oral cavity being covered with a biocompatible, inert membrane that is impermeable to the therapeutic and/or diagnostic agent(s) to be delivered.

## Claims

### Claim 1

A formulation for delivery of an agent to a site in a mucosal cavity, the formulation comprising
a mucoadhesive polymeric matrix having nanoparticles containing therapeutic, prophylactic, diagnostic, or nutraceutical agent incorporated therein, which is taste masked or targeted to a tissue upon release in the mucosal cavity,
wherein the matrix has at least two surfaces, a first surface for contacting the site in the mouth for delivery of the agent, and a second surface exposed to the oral cavity,
wherein the first surface of the matrix comprises polymeric material having a molecular weight and density on the surface of the matrix to facilitate passage of the nanoparticles through the mucosa of the oral cavity, and
wherein the second surface of the matrix comprises a coating or film impermeable to passage of the agent to be delivered.

### Claim 2 (depends on 1)

The formulation of claim 1 wherein the matrix comprises nanoparticles of chitosan or cyclodextrin having agent incorporated therein.

### Claim 3 (depends on 1)

The formulation of claim 1 wherein the coating or film is formed of a polymer selected from the group consisting of hydropropylmethylcellulose, cellulose acetate, and polyacrylamides.

### Claim 4 (depends on 1)

The formulation of claim 1 wherein the nanoparticles have a diameter between about 60 and 450 nm.

### Claim 5 (depends on 1)

The formulation of claim 1 wherein the nano particles are coated with polyalkylene glycol moieties to enhance penetration through the mucosa to the site for delivery.

### Claim 6 (depends on 1)

The formulation of claim 1 wherein the nanoparticles comprise targeting moieties on their surface to direct the nanoparticles to the site for delivery of agent.

### Claim 7 (depends on 1)

The formulation of claim 1 wherein the matrix comprises attachment peptides effective to adhere the matrix to the tissue of the site where the agent is to be delivered.

### Claim 8 (depends on 1)

The formulation of claim 1 wherein the agent is selected from the group consisting of chemotherapeutics, antiinfectives, anti-inflammatories, immunomodulators, vaccines, and combinations thereof.

### Claim 9 (depends on 8)

The formulation of claim 8 wherein the antiinfectives are selected from the group consisting of antibiotics, antifungals, antivirals, and combinations thereof.

### Claim 10 (depends on 1)

The formulation of claim 1 wherein the diagnostic agent is an imaging agent selected from the group consisting of iron oxide, gadolinium complex, radioisotopes, gold and combinations thereof.

### Claim 11 (depends on 1)

The formulation of claim 1 wherein the agent is a platinum based chemotherapeutic.

### Claim 12 (depends on 1)

The formulation of claim 1 further comprising one or more permeation enhancers.

### Claim 13 (depends on 12)

The formulation of claim 12 wherein the permeation enhancer is selected from the group consisting of 2-Dimethylaminopropionic acid dodecyl ester, polyethyleneglycol, citric acid, bile salt, and beta-cyclodextrin.

### Claim 14 (depends on 1)

The formulation of claim 1 comprising one or more taste-masking agents.

### Claim 15 (depends on 14)

The formulation of claim 14 wherein the taste masking agent is selected from the group consisting of citric acid, sweeteners, and food flavoring agents.

### Claim 16 (depends on 1)

The formulation of claim 1 further comprising an anti-inflammatory or antioxidant agent.

### Claim 17 (depends on 5)

The formulation of claim 5 wherein the polyalkylene glycol moieties are polyethyleneglycol having a molecular weight of less than 10,000 Da.

### Claim 18 (depends on 6)

The formulation of claim 6 wherein the moieties are RGD peptides.

### Claim 19 (depends on 1)

The formulation of claim 1 wherein the polymeric matrix material is chitosan, the chitosan taste masks the agent to be delivered and the chitosan releases the nanoparticles upon exposure to the pH of the oral cavity.

### Claim 20 (depends on 19)

The formulation of claim 19 wherein the nanoparticles release chemotherapeutic agents or diagnostic agents upon exposure to the pH of the oral cavity.

### Claim 21 (depends on 1)

A method of delivering an agent to a site in a mucosal cavity comprising administering to the region the formulation of claim 1.

### Claim 22 (depends on 21)

The method of claim 21 wherein the site comprises cancer cells.

### Claim 23 (depends on 21)

The method of claim 21 wherein the site comprises oral, buccal or sublingual mucosa.

### Claim 24 (depends on 21)

The method of claim 21 wherein the agent is delivered in a dosage not causing systemically effective levels of the agent.
